Guardant Health has stopped a trial of a minimum residual disease (MRD) test early after seeing the results of an interim analysis.
The study, called COBRA, was evaluating the ability of Guardant’s MRD blood test to improve outcomes in patients with stage II colon cancer after surgery. Patients underwent circulating tumor deoxyribonucleic acid testing to inform further treatment.
